The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has received the 9th Bioindustry Award from the Japan Bioindustry Association for the drug discovery research of lecanemab (Leqembi®), an antibody treatment for early Alzheimer's disease.
The treatment, co-developed by BioArctic and Eisai, is based on Professor Lars Lannfelt's discoveries about amyloid-beta protein's role in Alzheimer's disease. Lecanemab works by binding to specific forms of amyloid-beta and helping clear it from the brain. Eisai leads the global development and regulatory submissions, with both Eisai and Biogen handling commercialization. BioArctic retains commercialization rights in the Nordic region in partnership with Eisai.
BioArctic AB (Nasdaq Stockholm: BIOA B) ha annunciato che il suo partner Eisai ha ricevuto il 9° Premio Bioindustry dall'Associazione Bioindustriale Giapponese per la ricerca sulla scoperta del farmaco lecanemab (Leqembi®), un trattamento con anticorpi per la fase iniziale della malattia di Alzheimer.
Il trattamento, sviluppato congiuntamente da BioArctic ed Eisai, si basa sulle scoperte del Professor Lars Lannfelt riguardo al ruolo della proteina amiloide-beta nella malattia di Alzheimer. Lecanemab agisce legandosi a specifiche forme di amiloide-beta, favorendone la rimozione dal cervello. Eisai guida lo sviluppo globale e le procedure regolatorie, mentre sia Eisai che Biogen si occupano della commercializzazione. BioArctic mantiene i diritti di commercializzazione nella regione nordica in collaborazione con Eisai.
BioArctic AB (Nasdaq Estocolmo: BIOA B) anunció que su socio Eisai ha recibido el 9º Premio Bioindustry de la Asociación Bioindustrial de Japón por la investigación en el descubrimiento del fármaco lecanemab (Leqembi®), un tratamiento con anticuerpos para la enfermedad de Alzheimer en fases tempranas.
El tratamiento, desarrollado conjuntamente por BioArctic y Eisai, se basa en los descubrimientos del Profesor Lars Lannfelt sobre el papel de la proteína amiloide-beta en la enfermedad de Alzheimer. Lecanemab actúa uniéndose a formas específicas de amiloide-beta y ayudando a eliminarla del cerebro. Eisai lidera el desarrollo global y las solicitudes regulatorias, mientras que Eisai y Biogen se encargan de la comercialización. BioArctic conserva los derechos de comercialización en la región nórdica en asociación con Eisai.
BioArctic AB (나스닥 스톡홀름: BIOA B)는 파트너인 Eisai가 9회 바이오인더스트리 상을 일본 바이오인더스트리 협회로부터, 초기 알츠하이머병 치료제인 lecanemab (Leqembi®)의 신약 발견 연구로 수상했다고 발표했습니다.
이 치료제는 BioArctic과 Eisai가 공동 개발했으며, Lars Lannfelt 교수의 알츠하이머병에서 아밀로이드 베타 단백질의 역할에 대한 발견을 기반으로 합니다. Lecanemab은 특정 형태의 아밀로이드 베타에 결합하여 뇌에서 이를 제거하는 데 도움을 줍니다. Eisai가 전 세계 개발과 규제 제출을 주도하며, Eisai와 Biogen이 상업화를 담당합니다. BioArctic은 Eisai와 협력하여 북유럽 지역에서 상업화 권리를 보유하고 있습니다.
BioArctic AB (Nasdaq Stockholm : BIOA B) a annoncé que son partenaire Eisai a reçu le 9e Prix Bioindustry de l'Association japonaise de la bioindustrie pour la recherche sur la découverte du médicament lecanemab (Leqembi®), un traitement par anticorps pour la maladie d'Alzheimer précoce.
Le traitement, co-développé par BioArctic et Eisai, repose sur les découvertes du professeur Lars Lannfelt concernant le rôle de la protéine amyloïde-bêta dans la maladie d'Alzheimer. Le lecanemab agit en se liant à des formes spécifiques d'amyloïde-bêta et en aidant à les éliminer du cerveau. Eisai dirige le développement mondial et les soumissions réglementaires, tandis qu'Eisai et Biogen assurent la commercialisation. BioArctic conserve les droits de commercialisation dans la région nordique en partenariat avec Eisai.
BioArctic AB (Nasdaq Stockholm: BIOA B) gab bekannt, dass sein Partner Eisai den 9. Bioindustry Award von der Japan Bioindustry Association für die Wirkstoffforschung zu lecanemab (Leqembi®), einer Antikörperbehandlung für frühe Alzheimer-Erkrankungen, erhalten hat.
Die Behandlung, die gemeinsam von BioArctic und Eisai entwickelt wurde, basiert auf den Entdeckungen von Professor Lars Lannfelt zur Rolle des Amyloid-Beta-Proteins bei Alzheimer. Lecanemab wirkt, indem es sich an spezifische Formen von Amyloid-Beta bindet und hilft, diese aus dem Gehirn zu entfernen. Eisai führt die globale Entwicklung und die Zulassungseinreichungen, während sowohl Eisai als auch Biogen die Vermarktung übernehmen. BioArctic behält die Vermarktungsrechte in der nordischen Region in Partnerschaft mit Eisai.
- None.
- None.
Professor Lars Lannfelt founded BioArctic together with Pär Gellerfors in 2003 to develop an antibody treatment based on Lannfelt's groundbreaking discoveries of the role of amyloid-beta protein in Alzheimer's disease. These discoveries are the basis for lecanemab, an antibody treatment developed in collaboration with the Japanese company Eisai. By binding to specific forms of amyloid-beta, which causes Alzheimer's disease, lecanemab helps to clear amyloid-beta from the brain, thereby altering the course of the disease.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region.
The information was released for public disclosure, through the agency of the contact person below, on July 16, 2025, at 9:30 a.m. CET.
For further information, please contact:
Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association |
View original content:https://www.prnewswire.com/news-releases/the-drug-discovery-research-for-lecanemab-awarded-the-9th-bioindustry-award-by-the-japan-bioindustry-association-302506572.html
SOURCE BioArctic
FAQ
What is the significance of the Bioindustry Award received by BioArctic's lecanemab research?
How does BioArctic's lecanemab (Leqembi) work in treating Alzheimer's disease?
Who are the key partners involved in lecanemab's development and commercialization?
Who discovered the technology behind BioArctic's lecanemab?
